Cara Therapeutics Inc (CARA)

13.28
0.07 0.53
NASDAQ : Health Care
Prev Close 13.21
Open 13.20
Day Low/High 13.08 / 13.34
52 Wk Low/High 4.26 / 23.61
Volume 268.40K
Avg Volume 2.40M
Exchange NASDAQ
Shares Outstanding 32.58M
Market Cap 435.61M
EPS -2.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cara Therapeutics Reports Second Quarter 2017 Financial Results

Cara Therapeutics Reports Second Quarter 2017 Financial Results

Conference call today at 4:30 p.m. ET

Trump's FDA: A Friendlier Biotech Sheriff

Trump's FDA: A Friendlier Biotech Sheriff

There still will be winners and losers, but the new administration's FDA is a net plus for the industry.

Cara Therapeutics Announces Summary Data From Phase 1 Trial Of Oral CR845 In Hemodialysis Patients With Chronic Kidney Disease

Cara Therapeutics Announces Summary Data From Phase 1 Trial Of Oral CR845 In Hemodialysis Patients With Chronic Kidney Disease

Tablet strengths exhibiting appropriate plasma levels identified for potential use in general CKD-associated pruritus patients

Mattel, Mazor, Raytheon: 'Mad Money' Lightning Round (7/10/17)

Mattel, Mazor, Raytheon: 'Mad Money' Lightning Round (7/10/17)

A look at Jim Cramer's thoughts on companies of interest to 'Mad Money' viewers.

Warren Buffett Has the Edge Over Paul Singer, Oncor CEO Tells TheStreet's Jim Cramer on 'Mad Money'

Warren Buffett Has the Edge Over Paul Singer, Oncor CEO Tells TheStreet's Jim Cramer on 'Mad Money'

Investors keep coming up with reasons to hate the bull market.

These Stocks Are Changing Directions

These Stocks Are Changing Directions

Bullish and bearish reversals in the market.

CARA Makes Notable Cross Below Critical Moving Average

CARA Makes Notable Cross Below Critical Moving Average

In trading on Monday, shares of Cara Therapeutics Inc crossed below their 200 day moving average of $13.51, changing hands as low as $12.31 per share. Cara Therapeutics Inc shares are currently trading down about 9.3% on the day.

CARA Crosses Above Average Analyst Target

In recent trading, shares of Cara Therapeutics Inc have crossed above the average analyst 12-month target price of $25.75, changing hands for $26.42/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Watching the Dip Buyers This Morning

Watching the Dip Buyers This Morning

It would be better from a trading standpoint for this market to sell off with some vigor.

Biotech Stocks Showing Signs Of Resurgence

MarketNewsUpdates.com News Commentary

AK Steel Holdings, Cara Therapeutics, Nucor, Smart and Final: 'Mad Money' Lightning Round

AK Steel Holdings, Cara Therapeutics, Nucor, Smart and Final: 'Mad Money' Lightning Round

Jim Cramer focuses in on AK Steel Holdings, Cara Therapeutics, Nucor, and Smart and Final Stores.

Bull's Death Is Greatly Exaggerated: Cramer's 'Mad Money' Recap (Tuesday 6/20/17)

Bull's Death Is Greatly Exaggerated: Cramer's 'Mad Money' Recap (Tuesday 6/20/17)

The real exaggeration, says Jim Cramer, may be the influence of the bond market. But you can't ignore bonds, either.

Apple Is a Very Strong Brand, and Jim Cramer Is Sticking With the Stock: Mad Money

Apple Is a Very Strong Brand, and Jim Cramer Is Sticking With the Stock: Mad Money

Go inside Jim Cramer's Apple call.

Charles Schwab, Essent Group, Cara Therapeutics, MGM Growth Properties: 'Mad Money' Lightning Round

Charles Schwab, Essent Group, Cara Therapeutics, MGM Growth Properties: 'Mad Money' Lightning Round

Jim Cramer is bullish on Charles Schwab, Essent Group, Cara Therapeutics, and MGM Growth Properties.

Launch of Cannabis ETF May Not Be Best Option for Investors

Launch of Cannabis ETF May Not Be Best Option for Investors

Although a cannabis ETF launched in April, investors are still likely to find more value in buying individual stocks in the sector, according to traders.

Foot Locker, Cara Therapeutics, National Grid, TripAdvisor: 'Mad Money' Lightning Round

Foot Locker, Cara Therapeutics, National Grid, TripAdvisor: 'Mad Money' Lightning Round

Jim Cramer is bullish on Foot Locker, Cara Therapeutics, National Grid, and Home Depot.

Step Away From the Ledge: Cramer's 'Mad Money' Recap (Wednesday 5/24/17)

Step Away From the Ledge: Cramer's 'Mad Money' Recap (Wednesday 5/24/17)

Jim Cramer says that when it comes to alarming negativity and ridiculous exuberance, both extremes are wrong; investors need to get real.

Six Flags, Cara Therapeutics, Hertz Global Holdings: 'Mad Money' Lightning Round

Six Flags, Cara Therapeutics, Hertz Global Holdings: 'Mad Money' Lightning Round

Jim Cramer is bullish on Six Flags and Cara Therapeutics, but he's bearish on General Motors and Pandora.

Ignore That Man in the White House? Cramer's 'Mad Money' Recap (Wednesday 5/10/17)

Ignore That Man in the White House? Cramer's 'Mad Money' Recap (Wednesday 5/10/17)

Jim Cramer says he's amazed that stocks -- and gold, even -- are just yawning at Trump's move to fire FBI Director Comey.

TheStreet Quant Rating: D (Sell)